Perspectives on Enquiry & Evidence
FDA Increases Calls for Manufacturers to Ensure Trial Diversity, but Does It Fall Short of Addressing Health Inequalities in Product Development?
The evidence is staggering on the unequal health burdens experienced by specific patient groups defined by ethnic, gender, or socioeconomic risk factors and the different health outcomes these groups may have in clinical trials. And while efforts have been made to address these inequalities, they are still falling short.
What it means to be a lead analyst on a Global COVID-19 Trial
Society of Clinical Trials names TOGETHER "Trial of the Year"
New Publication on Adaptive Platform Trials
Program and Portfolio Optimization: A New Paradigm
Cyrus Mehta on Increasing the Power of Platform Trials
Advantages of platform designs for investigating COVID-19 therapies
Novel Adaptive Platform Trial for COVID-19 Therapies
Webinar - Practical Model-based Approaches for Phase I Oncology Trials
Significance of Bayesian Model-Based Approaches in Oncology Trials: An Interview with Dr. Satrajit Roychoudhury
Webinar Replay: Innovative Drug Development at a Glance
Implications for the Future of Drug Development in Emerging Economies
Interview with Zoran Antonijevic on Adaptive Design Methods
COVID-19: Trials, Designs and Tools for Promising Results - A Virtual Panel Discussion
Subscribe to our weekly newsletter
By submitting you agree to Cytel’s Privacy Notice